MedTrace Logo

JASAP: Japanese Aggrenox Stroke Prevention vs. Aspirin Programme

NCT00311402 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1295

Last updated 2014-02-14

Study results available
· View outcomes & findings →

Summary

Phase III study to compare the preventive effect of recurrent brain infarction and safety of Aggrenox (combination drug containing sustained-release dipyridamole 200 mg/acetylsalicylic acid 25 mg) twice daily vs. acetylsalicylic acid 81 mg once daily

Conditions

  • Cerebrovascular Accident

Interventions

DRUG

Aggrenox capsule

extended-release dipyridamole 200 mg plus ASA 50 mg in a capsule, 2 capsules twice daily

OTHER

Acetylsalicylic Acid (ASA)

Acetylsalicylic Acid (ASA) 81 mg, 1 tablet once daily

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Study Design

Purpose
PREVENTION
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-04-30
Primary Completion
2009-03-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00311402 on ClinicalTrials.gov